---
title: "ERAS INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Erasca, Inc."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286975698.md"
description: "Kirby McInerney LLP is investigating potential claims against Erasca, Inc. (NASDAQ:ERAS) regarding possible violations of federal securities laws following a patent infringement allegation from Revolution Medicines. This news caused Erasca's stock to drop by approximately 48%. No lawsuit has been filed yet, and the investigation is ongoing. Investors with information or interest are encouraged to contact the law firm."
datetime: "2026-05-19T23:12:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286975698.md)
  - [en](https://longbridge.com/en/news/286975698.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286975698.md)
---

# ERAS INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Erasca, Inc.

**ERAS INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Erasca, Inc.**

The law firm of Kirby McInerney LLP continues its investigation on behalf of Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ:ERAS) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.

\[LEARN MORE ABOUT THE INVESTIGATION\]

**What Happened?**

On April 28, 2026, Erasca disclosed receipt of a letter from Revolution Medicines alleging that Erasca’s ERAS-0015 (Erasca’s Phase-1 oral pan-RAS molecular glue inhibitor designed to target cancers) infringes a Revolution patent and is connected to alleged trade secret misappropriation. On this news, the price of Erasca’s shares declined by $9.25 per share, or approximately 48%, from $19.15 per share on April 27, 2026 to close at $9.90 on April 28, 2026.

**What Should I Do?**

At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.

If you purchased or otherwise acquired Erasca securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

\[LEARN MORE ABOUT SECURITIES CLASS ACTIONS\]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Kirby McInerney LLP  
Lauren Molinaro, Esq.  
212-699-1171  
https://www.kmllp.com  
https://securitiesleadplaintiff.com/  
investigations@kmllp.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20260519928781/en/

### Related Stocks

- [ERAS.US](https://longbridge.com/en/quote/ERAS.US.md)
- [RVMD.US](https://longbridge.com/en/quote/RVMD.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [RVMDW.US](https://longbridge.com/en/quote/RVMDW.US.md)

## Related News & Research

- [Erasca Touts 'Eye-Popping' ERAS-0015 Lung Cancer Data, FDA Path at BofA Conference](https://longbridge.com/en/news/286652404.md)
- [Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report](https://longbridge.com/en/news/286590889.md)
- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)
- [US Cancer Clinics Rush to Access Revolutionary Pancreatic Cancer Drug Daraxonrasib](https://longbridge.com/en/news/286405546.md)
- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)